On Feb 04, 2026, LLY reported earnings of 7.54 USD per share (EPS) for Q4 25, beating the estimate of 6.73 USD, resulting in a 11.92% surprise. Revenue reached 19.29 billion, compared to an expected 18.14 billion, with a 6.36% difference. The market reacted with a +10.33% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 12 analysts forecast an EPS of 7.68 USD, with revenue projected to reach 17.40 billion USD, implying an increase of 1.86% EPS, and decrease of -9.81% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ABBVIE INC.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$2.70
Actual
$2.71
Surprise
+0.17%
Novartis AG
Report Date
Feb 04, 2026 For Q4 25
Estimate
$2.02
Actual
$2.02
Surprise
+0.27%
Merck & Co., Inc.
Report Date
Feb 03, 2026 For Q4 25
Estimate
$2.02
Actual
$2.04
Surprise
+0.52%
Novo-Nordisk A/S
Report Date
Feb 04, 2026 For Q4 25
Estimate
$5.97
Actual
$6.32
Surprise
+5.77%
Pfizer Inc.
Report Date
Feb 03, 2026 For Q4 25
Estimate
$0.57
Actual
$0.66
Surprise
+14.29%
Sanofi - ADR
Report Date
Jan 29, 2026 For Q4 25
Estimate
$1.46
Actual
$1.53
Surprise
+4.22%
FAQ
What were Eli Lilly & Co.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Eli Lilly & Co. reported EPS of $7.54, beating estimates by 11.92%, and revenue of $19.29B, 6.36% above expectations.
How did the market react to Eli Lilly & Co.'s Q4 2025 earnings?
The stock price moved up 10.33%, changed from $1.00K before the earnings release to $1.11K the day after.
When is Eli Lilly & Co. expected to report next?
The next earning report is scheduled for Apr 30, 2026.
What are the forecasts for Eli Lilly & Co.'s next earnings report?
Based on 12
analysts, Eli Lilly & Co. is expected to report EPS of $7.68 and revenue of $17.40B for Q1 2026.